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Over 400 variants in the cystic ﬁbrosis (CF) transmembrane conductance regulator (CFTR) are CF-causing. CFTR modulators target
variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing
variants highlighting unmet needs. Alternative epithelial ion channel/transporters such as SLC26A9 could compensate for CFTR
dysfunction, providing therapeutic targets that may beneﬁt all individuals with CF. We investigate the relationship between
rs7512462, a marker of SLC26A9 activity, and lung function pre- and post-treatment with CFTR modulators in Canadian and US CF
cohorts, in the general population, and in those with chronic obstructive pulmonary disease (COPD). Rs7512462 CC genotype is
associated with greater lung function in CF individuals with minimal function variants (for which there are currently no approved
therapies; p = 0.008); and for gating (p = 0.033) and p.Phe508del/ p.Phe508del (p = 0.006) genotypes upon treatment with CFTR
modulators. In parallel, human nasal epithelia with CC and p.Phe508del/p.Phe508del after Ussing chamber analysis of a
combination of approved and experimental modulator treatments show greater CFTR function (p = 0.0022). Beyond CF, rs7512462
is associated with peak expiratory ﬂow in a meta-analysis of the UK Biobank and Spirometa Consortium (p = 2.74 × 10−44) and
provides p = 0.0891 in an analysis of COPD case-control status in the UK Biobank deﬁned by spirometry. These ﬁndings support
SLC26A9 as a therapeutic target to improve lung function for all people with CF and in individuals with other obstructive lung
diseases.
npj Genomic Medicine (2022)7:28 ; https://doi.org/10.1038/s41525-022-00299-9

INTRODUCTION
Cystic Fibrosis [CF (MIM:219700)] is a common life-limiting
autosomal recessive genetic disease caused by pathogenic
variants in the cystic ﬁbrosis transmembrane conductance
regulator (CFTR; MIM:602421). CF affects multiple organs; morbidity in the pancreas and intestine are seen at birth1–3, while
progressive lung disease is experienced throughout the course of
disease and is the major cause of morbidity and mortality.
Variability in disease severity across the affected organs is due, in
part, to variation in other genes, referred to as modiﬁer genes.
Modiﬁer genes impact phenotypic expressivity in the presence of
a dysfunctional major causal gene, for example, CFTR1,4–7.
CFTR is localized to the cell membrane of epithelial cells and
functions as an ion channel. Over 400 variants have been
reported to cause CF through variable effects on protein

function8 (http://cftr2.org). CF-causing mutations impact apical
chloride and bicarbonate transport, altering hydration and pH of
airway surface liquid resulting in viscous mucus. Accumulation
of this viscous mucus leads to cycles of infection and
inﬂammation, obstructing and damaging the airways, resulting
in progressive lung damage and end-stage lung disease9.
Developments in CF therapeutics over the past decade have
been transformative, altering the management paradigm from
treating the downstream consequences of dysfunctional CFTR and
delaying the progression of the disease, to treating the basic
defect in an individual’s CFTR itself: precision medicine. New drugs
enhance CFTR function by directly targeting the different defects
in the protein. For example, individuals with gating mutations
have access to a highly effective modulator, ivacaftor (IVA), which
is a potentiator that increases the opening probability of CFTR to
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aid chloride and bicarbonate ion transport in CF epithelia10. The
most common CF causing allele Phe508del (c.1521_1523delCTT;
p.Phe508del)11 displays minimal CFTR at the apical membrane due
to processing defects5,6, and once at the cell surface the
Phe508del protein exhibits reduced opening probability and
stability. Pharmaceuticals targeting this defect include a combination therapy of IVA and a CFTR corrector lumacaftor (LUM) or
tezacaftor (TEZ) that improves the Phe508del processing to
increase cell surface localized protein as well as channel gating.
More recently, triple combination therapy of another corrector,
elexacaftor, combined with tezacaftor and ivacaftor (ETI) has been
approved in the United States (US) for individuals with at least one
Phe508del aged 6 and above or other mutations responsive to
Trikafta (https://www.cff.org/Trials/Pipeline/details/10150/Elexacaf
tor-tezacaftor-ivacaftor-Trikafta). Elexacaftor stabilizes the protein
within the cell membrane, resulting in greater improvements in
lung function over LUM/IVA or TEZ/IVA alone12,13. ETI is now
indicated by the FDA for 90% of individuals with CF (https://www.
fda.gov/news-events/press-announcements/fda-approves-new-br
eakthrough-therapy-cystic-ﬁbrosis).
Although signiﬁcant progress has been made in the development of pharmaceuticals for precision medicine in CF, several
challenges remain. First, not all individuals with CFTR genotypes
for which eligible pharmaceuticals are available respond to those
treatments. Second, for those who do show a positive improvement in lung function, there is signiﬁcant variability in the
response12–15, which could be augmented with additional
therapies. Third, there are loss of function alleles that cannot be
addressed using the current paradigm, and therefore an
alternative approach to therapy beyond potentiators and correctors of CFTR is necessary.
Several alternative approaches are being actively pursued,
including CFTR gene restoration and/or correction or alternative
targets9. Conceptually, alternative targets to CFTR aim to
compensate for the abnormal dehydrated airway surface liquid
that results from dysfunctional CFTR by modulating other ion
channels, transporters and pumps16–20. This would provide
therapeutic options for those individuals with genotypes that do
not produce CFTR protein and could assuage limited responses to
existing CFTR modulators.
The clinical success rate of drugs in development is appreciably
higher when there is human genetic evidence that supports a
drug target21. Genome-wide modiﬁer gene studies in CF have
aimed to identify genetic loci that impact disease severity in the
presence of CFTR dysfunction in a hypothesis-free approach.
Identiﬁed in a genome-wide association study (GWAS) of intestinal
obstruction (meconium ileus) in CF7, the C allele of rs7512462 in
intron 5 of Solute Carrier Family 26 member 9 (SLC26A9)
(chr1:205899595, GRCh37) has since consistently demonstrated a
beneﬁcial effect for several CF co-morbidities, including in the
exocrine2,3 and endocrine pancreas4,22. These co-morbidities
appear to originate from pre-natal dysfunction in the CF
pancreas1,3,23. According to the Genotype Tissue Expression
project24 (GTEx; http://www.gtexportal.org/home/), rs7512462 is
an expression quantitative locus (eQTL) for SLC26A9 where the C
allele is associated with greater expression in the adult pancreas
(p = 1.2 × 10−5, normalized expression effect size = 0.27).
Rs7512462 and additional SLC26A9 eQTLs in the region of chr1:
205,806,897- 206,006,897(GRCh37) colocalize with the meconium
ileus CF GWAS summary statistics1, supporting gene expression
variation is responsible for the observed CF GWAS ﬁnding.
Given the importance of attenuating progressive lung disease in
CF, there was signiﬁcant interest in investigating the contribution
of SLC26A9 to lung function despite a lack of association evidence
with rs7512462 across a broad CF population, including the largest
CF GWAS of lung function to date5. SLC26A9 is an anion chloride
channel/transporter in epithelial cells that contributes to constitutive apical chloride conductance and enhances cAMP-regulated
npj Genomic Medicine (2022) 28

CFTR currents25–28 and Slc26a9−/−/Cftr−/− mice show worse postweaning survival over Cftr−/− models29. Rs7512462 appears to
associate with both the residual and activated current in lung
cells30,31. In individuals with CFTR variants that maintain apical
membrane localization, rs7512462 showed evidence of association with CF lung function31 and the relationship was greatly
enhanced upon treatment with the CFTR modulator IVA where the
C allele was associated with greater lung function improvement31,32. That rs7512462 was not shown to be a strong modiﬁer
of CF lung disease5,31 in the absence of treatment with CFTR
correctors but is associated with lung function in a non-CF
population study9,33 is consistent with functional studies, where
differential SLC26A9 interaction with wild-type CFTR and with
Phe508del-CFTR in human bronchial epithelia (HBE) has been
reported25,31.
The functional and CF population studies highlight the potential
of SLC26A9 as a target to improve CF outcomes across the
affected organs and to improve response to approved CFTR
modulators. However, several questions remain including whether
population studies support SLC26A9 as providing alternative
chloride transport in individuals with genotypes for which there
are no approved therapies; whether enhancing SLC26A9 will
improve lung function response to CFTR modulators targeting the
most common Phe508del variant; which patient-speciﬁc cellbased models of the airway demonstrate SLC26A9 expression; and
whether enhancing SLC26A9 could beneﬁt other obstructive lung
diseases such as chronic obstructive pulmonary disease (COPD) in
light of the rs7512462 association with lung function in non-CF
population studies33.
Through continued recruitment into the Canadian CF Gene
Modiﬁer Study (CGMS; a registry-based observational genetics
study) and in collaboration with the US Part B Cystic Fibrosis
Foundation Therapeutics PROSPECT observational study of modulator treatment34 (https://clinicaltrials.gov/ct2/show/NCT02477319),
we investigate the association between rs7512462 and (1) lung
function in individuals with CF with different CFTR genotypes
including variants that result in no CFTR protein product (i.e.
minimal function alleles); (2) individual lung function responses to
CFTR modulators IVA and LUM/IVA; (3) CFTR function in primary
cultured human nasal epithelia (HNE) from individuals with CF in
response to approved and experimental CFTR modulators; and (4)
other phenotypes in non-CF populations to inform the clinical utility
of SLC26A9 modulators beyond applications in CF.
RESULTS
The CGMS has enrolled 3257 participants from 9 provinces and 35
clinics across Canada with a range of CFTR genotypes that are
reﬂective of the Canadian CF population. To investigate the
association between rs7512462 and pre-treatment lung function,
we speciﬁcally study the subgroups of the CGMS who are: (1)
homozygous for Phe508del; (2) carrying at least one copy of the
G551D (c.1652G > A;p.Gly551Asp) variant or another gating variant
approved for IVA; and (3) individuals with two minimal function
(MF) variants in trans (https://www.cff.org/research-clinical-trials/
types-cftr-mutations) for which there are no CFTR modulators
approved (these include nonsense, splicing and small indel
variants) (Fig. 1). A subset of these individuals homozygous for
Phe508del or having at least one gating mutation have been
prescribed a CFTR modulator (Table 1; Fig. 1) and we investigate
the lung function response to LUM/IVA in this CGMS subset and in
an independent sample of 91 participants from PROSPECT, an
observational study in the US (Supplementary Table 1 for sample
exclusion). Participants from the PROSPECT study were younger
and healthier than the Canadian cohort (as measured by forced
expiratory volume in one second (FEV1) percent predicted
(FEV1pp)) at treatment initiation (Table 1).
Published in partnership with CEGMR, King Abdulaziz University
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Fig. 1 Assessment of the association of rs7512462 in the Canadian CF Gene Modiﬁer Study (CGMS) population broken down according
to particular sub-study groups. Sample sizes indicated in parentheses represent the overlap with those published in Strug et al.31. MF
minimal function variants; HNE human nasal epithelial. *This analysis is combined with the US PROSPECT cohort.

Rs7512462 is associated with CF lung function in the absence
of treatment
Using the International CF Gene Modiﬁer consortium lung
phenotype, Saknorm35 (Methods), we compared pre-treatment
lung function across the three CFTR genotype groups (Fig. 1).
Saknorm measures differ signiﬁcantly between individuals with a
gating variant (n = 89) versus those who are homozygous for
Phe508del (n = 1,266; effect size = 0.20, p = 0.030), while individuals with two MF variants (n = 63) do not differ in Saknorm from
Phe508del homozygotes (effect size = −0.11, p = 0.27).
In CGMS participants with at least one G551D variant (n = 79),
rs7512462 did not reach statistical signiﬁcance at the 0.05 level
with Saknorm (effect size = 0.185, p = 0.225, Supplementary Table
2). Meta-combining the CGMS association evidence with association results from four independent cohorts – a cohort from the
French gene modiﬁer study (FGS) with n = 49 participants32 and
three cohorts with n = 272 participants reported in Eastman
et al.36 – results in an effect size of 0.11 with p = 0.05 and an effect
size = 0.12 with p = 0.036 from inverse variance weighted and
from sample size weighted meta-analyses, respectively (Supplementary Fig. 1; Supplementary Table 2). Meta-analysis of the
rs7512462 Saknorm association from the FGS32 and CGMS cohorts
with at least one gating variant approved for ivacaftor have similar
but more variable effect size than that from the G551D subset
(effect size = 0.12 with p = 0.18; Supplementary Table 2).
In individuals from the CGMS who are homozygous Phe508del
(n = 1266), each C allele is associated with an increase in lung
function, albeit with a smaller effect size (effect size = 0.069, p =
0.028, Fig. 2a; Supplementary Fig. 2). Meta-analysis of this CGMS
association with an rs7512462 Saknorm association in n = 1804
individuals who are Phe508del/Phe508del from the FGS32 also
show association in both inverse variance weighted (effect size =
0.050, p = 0.021) and sample size weighted (effect size = 0.046,
p = 0.037) meta-analyses (Supplementary Fig. 2; Supplementary
Table 2). Constructing haplotypes in the CGMS in individuals
homozygous for Phe508del as in Lam et al.37 does not provide
evidence for signiﬁcant low risk (LR) or high risk (HR) haplotypes
contributing to Saknorm variation (Supplementary Table 3) and
does not provide greater power than using the single SNP
rs7512462 to mark the locus for association with lung function
(Supplementary Note; Supplementary Table 3).
Importantly, in individuals with two MF variants, the CC
genotype is associated with improved lung function when
compared to individuals with the TT and TC genotype (effect
Published in partnership with CEGMR, King Abdulaziz University

size = 0.45, p = 0.0083, Fig. 2a). This is consistent with the
hypothesis that for rs7512462 marking SLC26A9 activity, SLC26A9
may be providing alternative chloride transport properties in
individuals with CFTR variants for whom no currently approved
therapies exist.
When combining CGMS participants from the three genotype
groups in a joint multivariable regression model to assess the
association with rs7512462, the C allele is associated with greater
lung function (p = 0.017 and 0.022 for additive and recessive
models, respectively, Table 2). Fitting an interaction term in this
multivariable model, the C allele does not demonstrate a
statistically signiﬁcant difference in effect size depending on
one’s CFTR genotype (interaction p-values 0.90 and 0.46 for
additive and recessive models, respectively).
Rs7512462 C allele is associated with improved response to
CFTR modulators
Newly recruited participants into the CGMS on IVA (n = 23) were,
on average, older and had worse baseline lung function than
those included in Strug et al.31 (Table 1). Despite the difference in
baseline characteristics and disease severity, we do observe
additional supportive evidence for improved lung function
response when combining the newly and previously recruited
participants (difference in FEV1pp pre and post treatment
initiation) in individuals with the CC genotype upon treatment
with IVA (effect size = 9.9, p = 0.03, Table 3; Fig. 2b). Results from a
linear mixed-effect model, which accounts for the longitudinal
nature of the data, provides consistent results (effect size = 12.76,
p = 0.025; Supplementary Table 4).
Through ongoing recruitment in the CGMS there were 104
participants prescribed LUM/IVA clinically (Table 1). In collaboration with the US PROSPECT observational study, we investigated
lung function response to LUM/IVA alone (n = 91) and in a
combined sample of n = 195 individuals homozygous for Phe508del stratiﬁed by rs7512462. Despite minimal clinical response to
LUM/IVA reported on average14, we do observe a signiﬁcant
improvement in lung function response in those with the CC
genotype (p = 0.002 in US PROSPECT and p = 0.006 for combined,
respectively; Table 3), akin to observations for IVA (Fig. 2b and 31),
and in studies of improved CFTR function with the rs7512462 C
allele in HNE30 and HBE18,31 cells obtained from individuals
homozygous for Phe508del. Thus, the rs7512462 genotype shows
improved response to the LUM/IVA combination therapy in
npj Genomic Medicine (2022) 28
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Table 1.

Characteristics of participants included for response to CFTR modulators from the CGMS and US PROSPECT studies.

Participants on CFTR modulator

CGMS participants

US PROSPECT
LUM/IVA (n = 91)

Participant characteristics

Characteristic values CGMS IVA (In Strug et al.31, CGMS IVA (new,
n = 23)
n = 22a)

rs7512462

TT/TC/CC

11/10/1

12/9/2

41/48/15

30/50/11

age

mean (range)

26.5 (6.1–58.3)

31.3 (14.0–55.3)

25.7 (10.5–55)

20.9 (6–57)

CGMS LUM/IVA
(n = 104)

age < = 12

5

0

2

23

age (12,20]
age (20,30]

4
3

3
11

38
38

27
24

age > 30

10

9

26

17

sex

female (%)

16 (72.7%)

13 (56.3%)

56 (53.8%)

52 (57.1%)

FEV1pp baseline

mean (range)

66.6 (30.7–90.4)

58.9 (30.9–89.6)

59.6 (30.8–95.5)

75.7 (31.7–95.8)

4 (1–6)

4 (1–20)

6 (1–33)

4 (2–4)

Number of post-treatment FEV1pp median (range)
in 400 days
a

one sample with FEV1pp baseline outside the inclusion criteria and another who received a lung transplant were removed.
The lung function measure used for the CFTR modulator study is forced expiratory volume in one second percent predicted (FEV1pp). A subset of n = 22
individuals from CGMS on IVA were included for analysis in Strug et al.31 while n = 23 are newly-recruited into the CGMS.

cohorts of CF patients who were monitored observationally during
their real-world experience with the approved modulators.
We investigated CFTR-mediated current in 36 cultured HNE
from CGMS participants homozygous for Phe508del upon
treatment with VX-770+VX-809 (as in Kmit et al.30, corresponding
to the IVA/LUM combination; VX-770 applied acutely) and upon
treatment with VX-770+VX-809+ an ampliﬁer under experimental
investigation38 (Fig. 3). We used the HNE from the earliest passage
available to us (P2) to align with Kmit et al.30. Deﬁning the
treatment response as the difference in ΔIeq -forskolin from DMSO
vehicle to VX-770 + VX809 (n = 36) or VX-770+ VX-809+ ampliﬁer
(n = 30), we see a signiﬁcant improvement in CFTR function in the
CC group (effect size = −1.934, p = 0.0022, Table 4) in HNE with
VX-770+VX-809+ ampliﬁer. The increase in CFTR function in the
CC group in the cultured HNE with VX-809 does not reach
statistical signiﬁcance (effect size = −0.406, p = 0.338, Table 4)
unlike previous reports in HNE and in HBE models, although the
direction of effect is consistent. This difference in effect size made
us question the SLC26A9 gene expression proﬁle across different
lung tissue models, especially given the low passage of the
primary HNE cultured cells studied by Kmit et al.30.
SLC26A9 expression differs across airway models
While investigating eQTLs in various airway tissue models, we
observed that there is no evidence supporting rs7512462 as an
eQTL in the lungs from GTEx v8 (p = 0.71) or from RNA obtained
from naïve HNE of individuals with CF (p = 0.64, n = 79) despite its
association with residual and activated current in Ussing chamber
studies30,31. SLC26A9 expression appears generally low across
several different lung model systems we investigated, with an
average of 1.34 transcripts per million (TPM) (Supplementary Fig.
3a). We generated a resource that contains the transcriptomes
from paired cultured and fresh naïve HNE and HBE tissue on the
same individuals (Methods; GEO ID: GSE172232)). Of the primary
lung cell models we investigated, the greatest expression is in the
naïve HBE cells (TPM = 1.94; Supplementary Fig. 3a), and this
expression level is 2.1-fold greater than in the naïve HNE (p = 0.04,
paired analysis in n = 17 HNE-HBE naïve pairs). Unfortunately,
naïve HBE cell models are not generally accessible for personalized medicine approaches39, and cultured models are the norm.
Here cultured HBE show mean expression with TPM = 1.71 that is
2.5-fold greater than the CF cultured HNE (p = 0.02, paired analysis
for n = 16 HNE-HBE cultured pairs), although there is some
npj Genomic Medicine (2022) 28

indication that a reduction in culturing time results in greater
SLC26A9 expression in the HNE (Supplementary Fig. 3b).
Using single-cell RNA-seq data catalogued in the Human Lung
Cell Atlas40, we investigated the expression of SLC26A9 and CFTR
across cell types. Within lung cells, both genes are expressed in
the epithelial cells of the alveoli and airway, particularly within
alveolar type 2 (AT2) cells and club cells (Fig. 4). These cell types
are also supported by single-cell Human Protein Atlas data41
(http://www.proteinatlas.org/), which reports expression in AT2
cells (normalized TPM of 50.1 for SLC26A9 and 65.6 for CFTR) and
club cells (normalized TPM of 2.7 for SLC26A9 and 17.8 for CFTR).
Furthermore, single-cell GTEx data42,43 (http://www.gtexportal.
org/home) shows concordant evidence where, SLC26A9 and CFTR
reads are observed in an appreciable fraction of AT2 cells (24.59%
CFTR, 12.41% SLC26A9) and club cells (28.79% CFTR, 5.45%
SLC26A9). We then assessed the evidence for CFTR-SLC26A9 coexpression among the club, basal and alveolar epithelial cell types
identiﬁed in the Human Lung Atlas study40. Both the Spearman’s
correlation and the zero-inﬂated negative binomial model
indicated signiﬁcant association between the CFTR and the
SLC26A9 read counts for AT2 cells (Table 5). The model estimate
suggests positive co-expression between the two genes (log
ratio = 0.00035, p = 0.00974, Table 5).
Phenome-wide Association Study (PheWAS) of rs7512462 and
colocalization analysis
We used the GWAS ATLAS database44 that includes 4756 GWAS
from 473 unique studies with 3302 unique traits, and the UK
Biobank resource to investigate other non-CF traits associated
with rs7512462. The 10 traits with the smallest reported p-values
are listed in Table 6, four of which are respiratory phenotypes from
the UK Biobank and Spirometa consortium33: peak expiratory ﬂow
(PEF), forced expiratory volume in one second and forced vital
capacity (FEV1/FVC) ratio. Saknorm, the lung function measurement used in the CF GWAS, is also calculated from FEV15,35. The list
of signiﬁcant phenotypes also includes our own CF modiﬁer gene
study where we identiﬁed rs7512462 as a modiﬁer of meconium
ileus, with evidence of an exocrine pancreatic origin1 (Table 6).
Interestingly, an earlier age at menarche (which is associated with
weight) and a higher male waist circumference and waist-hip ratio
are also associated with the rs7512462 C allele. The association of
rs7512462 with type 1 diabetes and the weight-related phenotypes suggest that the role rs7512462 is marking in these
reproductive and metabolic phenotypes may likewise trace back
Published in partnership with CEGMR, King Abdulaziz University
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Fig. 2 Participant lung function or lung treatment response categorized by rs7512462 genotype. a Boxplot includes an overlay with a
stripchart of lung function from CGMS participants prior to modulator treatment, measured as Saknorm across different CFTR mutation
groups. Saknorm5,35 is calculated with FEV1 measurements taken prior to modulator treatment, if applicable. b Boxplot includes an overlay
with a stripchart for treatment response in patients on IVA (n = 45), LUM/IVA in PROSPECT cohort (n = 91) or LUM/IVA in combined PROSPECT
and CGMS samples (n = 195). Following Strug et al.31, the treatment response for IVA is deﬁned as the difference between the mean posttreatment FEV1pp within 15 to 400 days and FEV1pp baseline. Response for LUM/IVA is deﬁned as the difference in FEV1pp between the ﬁrst
post treatment within 5 to 7 months to the baseline65 (Methods). The center line, upper and lower box limits of boxplots correspond to the
median, the third quartile (Q3) and the ﬁrst quartiles (Q1), respectively; whiskers reﬂect the 1.5x interquartile range (IQR), i.e., bottom whisker
is Q1-1.5xIQR and upper whisker is Q3 + 1.5 x IQR. Each dot represents an individual measurement.

to an exocrine pancreatic origin. Signiﬁcant colocalization analysis
(column ‘Colocalization P-value’, Table 6) calculated using the
Simple Sum1,45 implemented in LocusFocus46 between the
meconium ileus CF GWAS statistics1 and the summary statistics
from the PheWAS associated traits supports that the same genetic
variation contributes to the different traits.
Airﬂow limitation is a key diagnostic feature of COPD47. In the
UK Biobank, we analyzed n = 22,071 of 263,461 participants with
moderate to severe airﬂow limitation deﬁned by the Global
Initiative for Obstructive Lung Disease (GOLD) criteria48. Although
rs7512462 is a modiﬁer of PEF and FEV1/FVC (p = 2.74 × 10−44 and
Published in partnership with CEGMR, King Abdulaziz University

p = 4.11 × 10−5, respectively) from Shrine et al.33 (Table 6), the
evidence is not as conclusive for FEV1pp and COPD case-control
status in the UK Biobank (p = 0.56, 0.0891, respectively; Fig. 5).
DISCUSSION
The availability of CFTR modulators is altering care for many
individuals with CF, although variation in response is apparent,
partially due to individual genetic backgrounds. One such genetic
factor is SLC26A9, which contributes to early onset CF comorbidities
in the pancreas and intestine1,4,22,37. Unlike for these early-onset
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Table 2.

Association between Saknorm and rs7512462 using additive
and recessive codings in the CGMS prior to treatment.
Models

Covariate

Additive

Effect size S.E.

P-value

rs7512462_C

0.072

CFTR-Gating/Other

0.210

0.094 0.025

–0.099
–0.244

0.099 0.317
0.050 1.41 ×
10−6

0.130
0.208

0.057 0.022
0.093 0.026

CFTR-MF/MF

–0.101

0.099 0.307

Saknorm new reference
equation

–0.244

0.050 1.32 ×
10−6

CFTR-MF/MF
Saknorm new reference
equation
Recessive rs7512462_CC
CFTR-Gating/Other

0.030 0.017

Saknorm is a continuous FEV1- based CF-speciﬁc percentile that is
normalized and accounts for age, sex and height and is survival
adjusted5,35. Saknorm5,35 is calculated with FEV1 measurements taken
prior to modulator treatment, if applicable. The combined samples include
individuals with gating mutations (n = 89), individuals homozygous for
Phe508del (n = 1266) or those with two minimal function (MF) mutations
(n = 63). All analyses use the robust covariance matrix estimates by the R
package ‘rms’66. In addition to rs7512462, both models include a CFTR
mutation group indicator, with reference group as homozygous Phe508del. Saknorm new reference equation is an indicator for the reference
equation used to calculate Saknorm (Methods) depending on the year the
lung function measurement was taken. Individuals with a gating variant,
individuals who are homozygous Phe508del or those who carry two MF
alleles are included.

Table 3.

Association of rs7512462 with CFTR modulator response.

Studies
IVA(CGMS)

LUM/IVA (US
PROSPECT)
LUM/IVA (US
PROSPECT + CGMS)

Covariates

Effect Size S.E.

Age at baseline

–0.077

0.095 0.419

FEV1pp at baseline –0.025

0.073 0.731

P-value

rs7512462_CC

9.905

4.477 0.033

Early CGMS Cohort

5.336

2.606 0.047

–0.188

0.074 0.014

FEV1pp at baseline –0.123

0.053 0.024

rs7512462_CC
Age at baseline

8.518
–0.119

2.657 0.002
0.064 0.066

Age at baseline

FEV1pp at baseline –0.069

0.037 0.066

rs7512462_CC

5.217

1.871 0.006

PROSPECT Cohort

0.865

1.401 0.540

CFTR modulator response is the difference between the FEV1pp after the
modulator response and the value at last visit before the treatment
initiation within 3 months as deﬁned in Methods. Increased Δ FEV1pp
indicates better treatment response. Sample sizes in each CFTR modulator
treatment group are n = 45 for IVA (CGMS), n = 91 for LUM/IVA (US
PROSPECT) and n = 195 for the combined LUM/IVA analysis of the US
PROSPECT and CGMS participants (US PROSPECT + CGMS). Early CGMS
Cohort for IVA-CGMS reﬂects an indicator for those participants that were
included in an earlier published study31. LUM/IVA studies were also
adjusted for population structure by principal components (PCs; n = 7 PCs
for US PROSPECT and n = 4 for US PROSPECT + CGMS). PROSPECT Cohort
is an indicator of whether the individual was a participant in the US
PROSPECT study or the CGMS. All results use robust variance estimates.

phenotypes where the rs71512462 SNP is a SLC26A9 eQTL in the
pancreas and SLC26A9 and CFTR appear to contribute to these
phenotypes independently1,7,31, in the lungs the mechanism that is
being marked by rs7512462 is not immediately obvious from the
npj Genomic Medicine (2022) 28

genetic data. Meanwhile, some have also questioned whether
rs7512462 is even associated with lung function36.
To address the connection between rs7512462 and SLC26A9,
we integrate evidence from population and functional studies.
The rs7512462 SNP was shown to associate with lung function
or lung response to CFTR-modulators in individuals that carry
CFTR variants that result in apical membrane localization for
CFTR31 and this is further supported here. Although rs7512462
does not show eQTL evidence based on lung tissue expression,
SLC26A9 is present in HBEs28,49,50 (Supplementary Fig. 3) and
Larsen et al.28 show that SLC26A9 is a major contributor to
constitutive anion secretion across HBEs. In Strug et al.31 Fig. 3B
prior to CFTR correction in Phe508del/Phe508del HBE monolayers, rs7512462 shows evidence of association with residual
forskolin-stimulated current (P = 0.09, −0.17 µA/cm2 ΔIeq-forskolin per C protective allele) in Ussing chamber studies. A
relation between rs7512462 genotype and transepithelial
current in uncorrected Phe508del CFTR was also shown by
others in HNE cultures with Phe508del CFTR genotypes30.
Experimental evidence for a relationship between the
rs7512462 genotype and CFTR function in airway cell models
and here in CF participant responses was also observed by
rescuing the trafﬁc-defective Phe508del with corrector modulators30,31. Published in vitro and cell studies have demonstrated a
CFTR-SLC26A9 interaction in lung cells and together with recent
work28,49,50 and references within, evidence is emerging that
SLC26A9 may also stabilize CFTR. Therefore, we interpret that the
contribution of SLC26A9 that rs7512462 is marking for lung
phenotypes may be from both anion channel activity and
enhancement of apical membrane-bound CFTR.
To address the uncertainty in evidence for rs7512462 association with lung function36, here we extend several genetic
association studies. We investigate the role of rs7512462 genotype
in CF patients with different types of CFTR mutations and in
treatment response to CFTR modulators both in patient populations and in airway models. We align the ﬁndings and previously
published work with gene expression patterns including understanding of cell type-speciﬁc SLC26A9 and CFTR co-expression, and
now also consider the role of rs751242 in the phenome and, in
particular, in lung function measurements in non-CF populations.
Signiﬁcant human genetic evidence that supports a role for
SLC26A9 in CF disease severity and CFTR modulator response is
accumulating. Here we provide a comprehensive investigation of
the role of rs7512462 as a marker of SLC26A9 activity in CF and
non-CF populations.
The relationship between the SLC26A9 rs7512462 marker and
lung function in three types of CFTR genotypes was revealing.
Individuals with the CF-causing G551D gating variant show
association with rs7512462. Gating-deﬁcient CFTR protein exhibits epithelial apical cell membrane localization with reduced
opening probability, resulting in reduced epithelial chloride and
bicarbonate secretion characteristic of CF51. In contrast, individuals homozygous for Phe508del, comprising the majority of CF
cases, show more modest evidence of association with rs7512462.
Phe508del-CFTR is rapidly degraded intracellularly with minimal
surface membrane localization. Meanwhile, we demonstrated
that individuals with MF variants do show rs7512462 association
but with the absence of CFTR protein cannot respond to CFTR
modulator therapy. The studies of MF alleles support that at least
some aspect of lung function contribution by SLC26A9 can be
independent of CFTR. These investigations align with several
previous studies highlighting the potential for SLC26A9 to
provide (alternative) chloride transport that functions independently of CFTR25,26.
CF GWAS of early-onset CF pancreatic and intestinal phenotypes were CFTR genotype independent1–3,7; that is, those
homozygous for Phe508del still demonstrated genome-wide
signiﬁcance with beneﬁt from the C allele of rs7512462, a marker
Published in partnership with CEGMR, King Abdulaziz University
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Fig. 3 Boxplot overlayed with stripchart for CFTR function by rs7512462 genotype in HNE cultured to P2. The CFTR function is deﬁned as
the difference in ΔIeq-forskolin from treatment with VX-770+VX-809 (left; n = 36) or VX-770+VX-809+ampliﬁer (right; n = 30) to DMSO
vehicle in CFTR-mediated current in cultured HNE from participants homozygous for Phe508del. More negative measurements reﬂect greater
CFTR function. The centerline, upper and lower box limits of boxplots correspond to the median, the third quartile (Q3) and the ﬁrst quartiles
(Q1), respectively; whiskers reﬂect the 1.5x interquartile range (IQR), i.e., bottom whisker is Q1-1.5xIQR and upper whisker is Q3 + 1.5 x IQR.
Each dot represents an individual measurement.

Table 4. Association of rs7512462 with change in function to
modulator treatment.
Studies

Covariates

Effect Size S.E.

CFTR-mediated current
(VX-770+VX-809)

rs7512462_CC

−0.406

CFTR-mediated current
(VX-770+VX-809+
ampliﬁer)

rs7512462_CC

P-value

0.417 0.3375

Standard media −1.969

0.456 0.0001

−1.934

0.572 0.0022

Standard media −2.170

0.697 0.0044

Forskolin-stimulated currents mediated by CFTR (measured as change in
current after application of forskolin, ΔIeq-forskolin) is used as the
treatment response; more negative values correspond to more CFTR
activity. Functional study includes HNEs from individuals homozygous for
Phe508del with VX-770+VX-809 (n = 36) and VX-770+VX-809+ ampliﬁer
(n = 30; a subset of the 36 samples tested with 770+VX-809) measured as
difference in CFTR-mediated current after applying forskolin regressed on
rs7512462 with a recessive coding. All results use robust variance
estimates.

of SLC26A9 gene expression in CF phenotypes that show pre-natal
onset (for example, meconium ileus). This may reﬂect that
SLC26A9 and CFTR may act independently at this stage of
development and is consistent with the observation that Slc26a9
mRNA was high in the murine pancreas in the embryonic stages of
development when Cftr was low31. Given the small sample size,
Published in partnership with CEGMR, King Abdulaziz University

the rs7512462 association with lung function in individuals with
two MF alleles requires further investigation and independent
replication. However, a consistent beneﬁcial effect of the CC
rs7512462 genotype across several of our independent studies
and disparate outcomes provides support that modulation of
SLC26A9 can provide alternative chloride transport and could be a
therapeutic target to improve lung function in individuals with
any CFTR genotype. The modulation of alternative channels,
transporters, and pumps to compensate for dysfunctional
CFTR19,52, and in particular SLC26A99,20,31, would provide a
mutation-agnostic approach and address the current unmet need
of CF individuals with MF alleles.
Given other published reports assessing the rs7512462 relationship with lung function in individuals with G551D variants31,32,36,
we used meta-analysis to summarize the current state of the
evidence. Together, the weight of evidence supports a relationship
between the SLC26A9 marker, rs7512462, and lung function in
individuals with a G551D variant where there is cell-surface
localized CFTR protein, but reduced activity. In an expanded CGMS
cohort, we also replicated the enhancing effect of the rs7512462 C
allele upon the rescue of gating variants with IVA, suggesting that
the pre-treatment effect may be reﬂective of constitutive activity
and/or attributable to SLC26A9-aided residual CFTR function.
Consistent with either is the suggestive association we observed
between rs7512462 and lung function prior to treatment with
LUM/IVA in individuals from the CGMS homozygous for Phe508del,
npj Genomic Medicine (2022) 28
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Fig. 4 CFTR and SLC26A9 single-cell expression from the Human Lung Cell Atlas40. a Lung cell expression proﬁles from three individuals
were clustered by nearest-neighbor and visualized using uniform manifold approximation and projection (UMAP). Normalized and log-scaled
RNA counts for CFTR and SLC26A9 are plotted for each cell. Tissue compartment as deﬁned by the Human Lung Cell Atlas is shown;
expression of both CTFR and SLC26A9 is primarily restricted to epithelial cells, b UMAP clustering of epithelial lung cells only; cell types were
annotated in the Human Lung Cell Atlas. c Breakdown of CFTR and SLC26A9 expression by cell type. Cells were grouped as having CFTR read
count > 1 (red), SLC26A9 > 1 (blue) or co-expressing both (purple). Cell total varies and is annotated for each cell type.

with a reduced effect size possibly reﬂective of reduced cell
membrane localization and interaction.
LUM/IVA was the ﬁrst approved modulator for those homozygous for Phe508del, on the basis of reduced pulmonary
exacerbations and lung function response. However, the average
improvement in lung function in clinical trials14 and observational
studies34 has been modest. To investigate whether the improvements in lung function from LUM/IVA are modiﬁed by the
rs7512462 genotype, we also genotyped the DNA from participants of the US observational LUM/IVA study, PROSPECT (https://
clinicaltrials.gov/ct2/show/NCT02477319), and demonstrated that
although modest in its average improvement in lung function,
those with the CC rs7512462 genotype did exhibit the greatest
beneﬁt. This ﬁnding of rs7512462 impact on clinical response in a
real-world setting of treated patients is consistent with published
studies of CFTR function in primary HBE and HNE cells from
individuals homozygous for Phe508del by us31 and others30,
respectively. Together these ﬁndings across the two treated CFTR
genotype groups replicate and expand previous reports25,26,30,31
that rs7512462 correlates with improved CFTR function.
We did evaluate CFTR function in nasal brushes from 36
individuals homozygous for Phe508del in Ussing chamber studies
following 24 h exposure to vehicle (DMSO), VX-770 with corrector
npj Genomic Medicine (2022) 28

VX-809 (corresponding to IVA/LUM), and a combination of VX-770,
VX-809, and an experimental ampliﬁer38. We observed a similar
trend to that reported in Kmit et al.30 with VX-809, although it did
not reach statistical signiﬁcance. When CFTR function was,
however, augmented with the ampliﬁer, the difference in CFTR
function pre- and post-treatment was greatest in the cells with the
rs7512462 CC genotype. These functional studies further support
the hypothesis that SLC26A9 will likely beneﬁt any therapeutic
situation with increased apical surface localized CFTR protein, such
as for the latest highly effective modulator treatment, ETI.
Although the population studies provide important insights
into the relationship between CFTR and SLC26A9 marked by
rs7512462 in vivo, functional studies in cellular and animal
models will be necessary to understand the functional relationship between the two channels/transporters53 and how they
may be working together. The expression studies presented
here provide guidance on the use of cellular models for SLC26A9
and further highlight potential limitations of cultured HNE for
the unique considerations of studying SLC26A9 and CFTR that
are distinct from the ones for studies of CFTR alone. Compared
to naïve bronchial cells, we observed greater variation and lower
expression in naïve nasal cells. Furthermore, the duration of
culturing time of either HNE or HBE cells resulted in reduced
Published in partnership with CEGMR, King Abdulaziz University
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Table 5.

40

Co-expression between SLC26A9 and CFTR using the Human Lung Cell Atlas data .

Cell Type

Number of cells

Zero-inﬂated negative binomial model
Effect size

Spearman’s correlation

S.E.

P-value

Rho

P-value

Club

895

−0.00007

0.00125

0.9564

0.05173

0.12196

AT2a

760

0.00035

0.00013

0.0097

0.13215

0.00026

Basal
AT1a

240
421

−11.6529
−8.41119

94.6542
152.863

0.9020
0.9561

−0.02365
−0.01178

0.71544
0.80962

AT2-sa

201

0.00004

Differentiating Basal

43

AT2 and AT2-s
AT1, AT2 and AT2-s

0.00143

0.00122

0.2433

0.28686

−0.02385

0.01931

0.2168

0.07235

961

0.00041

0.00014

0.0036

0.16567

<0.0001

1382

0.00048

0.00015

0.0018

0.32261

<0.0001

0.64478

The effect size estimate from zero-inﬂated negative binomial model indicates log-ratio relations between CFTR and SLC26A9 expression. Values greater than zero
correspond to positive co-expression. Spearman’s correlation estimates (rho) were calculated using log-transformed read counts per million measures for CFTR
and SLC26A9. The Spearman’s correlation and the zero-inﬂated negative binomial model analysis were performed by R function cor.test() and the zeroinﬂ()
function in the package pscl90, respectively. All p-values indicate two-sided statistical test results.
a
AT2 Alveolar Epithelial Type 2; AT1 Alveolar Epithelial Type 1; AT2-s Signaling Alveolar Epithelial Type 2

Table 6.
PMID
30804560
30804560

The 10 phenotypes with smallest rs7512462 association p-value obtained from the GWAS ATLAS44.
Domain
Respiratory
Respiratory

Trait

Effect Size
0.038

PEF (UKBB)
PEF (Meta of UKBB and Spirometa)

0.037

P-value at rs7512462

N

Colocalization P-value

46

321,047

2.24 x 10−9

−44

345,265

2.82 × 10−8

−9

4.33 × 10

2.74 × 10

30807572

Gastrointestinal

Meconium ileus in CF

−0.289

1.86 × 10

6770

NA

28436984
30804560

Reproduction
Respiratory

Age at menarche
FEV1/FVC ratio (Meta of UKBB and Spirometa)

−0.021
0.01

3.93 × 10−6
4.11 × 10−5

252,514
400,102

3.63 × 10−8
6.03 × 10−9

30804560

Respiratory

FEV1/FVC ratio (UKBB)

0.01

1.44 × 10−4

23754948
25231870

Metabolic
Reproduction

Waist circumference (male)
Age at menarche

0.03
−0.023

321,047

2.24 × 10−8

−4

36,231

7.08 × 10−9

−4

132,989

7.41 × 10−9

2.2 × 10
3.2 × 10

−4

19430480

Endocrine

Type 1 Diabetes

NA

7.47 × 10

7982

NA

23754948

Metabolic

Waist-hip ratio (male)

0.028

7.7 × 10−4

34,629

1.78 × 10−8

The colocalization p-value assesses evidence for common genetic contributions between the corresponding study phenotype and the meconium ileus CF
GWAS1 at chr1:205,895,000-205,921,000 locus. The effect allele in all studies is C, and the other allele is T, except for type 1 diabetes, where the effect size is not
reported for the SNP in the original summary statistics from the listed publication (PMID). PheWAS signiﬁcance level is p < 1.05 × 10−5 after adjusting for 4756
GWAS in the database (alpha 0.05). UKBB refers to an analysis using the UK Biobank. ‘Colocalization P-value’ represents the p-values from the colocalization
analysis calculated here with the CF GWAS summary statistics in Gong et al.1 for the corresponding phenotype, using LocusFocus46 calculated on the chr1:
205,895,000-205,925,000 region in hg19. NA in this column reﬂects a lack of information available to carry out the colocalization analysis.

SLC26A9 expression. Presently, the cultured HBE model appears
superior to HNEs for investigations of SLC26A9, although further
investigation of culturing conditions and of cell differentiation
should be considered.
Interestingly, the most signiﬁcant SLC26A9 locus SNPs from the
CF GWAS1,7 also associate with lung function measurements in
several large international studies: PEF and FEV1/FVC ratio in
participants from the UK Biobank aged 40–699,33; PEF and FEV1/
FVC ratio in the Spirometa consortium33; and for the FEV1/FVC
ratio in 8-year-olds from the UK10K consortium54. These results
align with our ﬁndings that, after correction of CF-causal CFTR
variants with modulators, SLC26A9 locus SNPs are associated with
improved lung function and CFTR function.
It is noteworthy that decreased spirometry is diagnostic for other
obstructive lung diseases such as COPD55. Several studies have
reported similar pathobiology cascades between CF and COPD due
to dysfunctional CFTR and environmental risk factors for
COPD56–60. For example, CFTR chloride channels show reduced
capacity as a result of tobacco smoke and may result in the mucus
obstruction characteristic of COPD59,61 that is akin to that seen in
Published in partnership with CEGMR, King Abdulaziz University

CF. If SLC26A9 augments chloride transport, SLC26A9 agonists
could also be an effective therapeutic strategy for COPD. In support
of this premise is the association evidence highlighted here
demonstrating rs7512462 is a modiﬁer of lung function in Shrine
et al.33, with signiﬁcant colocalization evidence between the CF
and their UK Biobank + Spirometa Consortium summary statistics
at the SLC26A9 locus, reﬂective of a common underlying genetic
contribution.
A role for SLC26A9 in the CF precision medicine landscape is an
exciting prospect. SLC26A9 shows desirable characteristics9 as an
alternative therapeutic target for CF, including the urgent need for
options for CF individuals with MF alleles. The association between
rs7512462 genotype and response to existing pharmaceuticals
indicate the potential to reﬁne personalized combinations of
modulators, and there is also support that SLC26A9 agonists may
yield beneﬁt to any existing pharmacological or gene correction
paradigm in CF, independent of CFTR genotype. Further research
should also address the potential for SLC26A9 agonists to improve
measures of lung function in non-CF populations.
npj Genomic Medicine (2022) 28
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Fig. 5 Lung function measures colocalize with CF meconium ileus GWAS at the SLC26A9 locus. Visualization of colocalization using
LocusFocus46. Peak expiratory ﬂow (PEF) GWAS summary statistics (n = 345,265) from Shrine et al.33 are shown as circles with corresponding
left y-axis against lines that trace (1) GTEx v7 adult lung eQTLs for SLC26A9; (2) meconium ileus GWAS1 summary statistics; (3) FEV1pp GWAS
summary statistics from UKBB participants (N = 263,461; 22,071 of which have COPD as per GOLD level 2-4 deﬁnitions); (4) FEV1/FVC ratio
GWAS summary statistics from Shrine et al.33 (highest effective sample size is 396,686, a function of sample size (N = 400,102) times
imputation quality); and (5) Chronic obstructive pulmonary disease (COPD) case-control association summary statistics (22,071 cases and
241,390 controls). The choice of y-axis scales and the primary dataset is for visualization purposes only and does not inﬂuence colocalization
test result conclusions. There is a known gap on the human reference GRCh37 at chr1:205,922,708-206,072,707, which corresponds to the
white gap in the ﬁgure as no variants exist. Lines traverse the lowest p-values per window as a visual guide (window size = 6.67 Kbp) with
corresponding right y-axis. A total of 85 SNPs in this region were used to test for colocalization using the Simple Sum method1,45. The Simple
Sum colocalization test1,45 is implemented in the grey region, which was selected to match the observed peak at chr1:205,899,000205,925,000. The color of the circles reﬂects the pairwise linkage disequilibrium (LD) with the rs7512462 lead SNP (purple) using the European
subset of the 1000 Genomes Project, with varying strength of LD depicted with a different colour as denoted in the legend.

METHODS
Ethics approval
The Canadian CF Gene Modiﬁer Study (CGMS) was approved by the
Research Ethics Board of the Hospital for Sick Children (# 0020020214 from
2012 to 2019 and #1000065760 from 2019-present) and all participating
sub-sites. Written informed consent was obtained from all participants or
parents/guardians/substitute decision makers prior to inclusion in the
study. The CGMS is also approved by the Research Ethics Board of the
Hospital for Sick Children for the usage of public and external data. The US
PROSPECT study provides data from a clinical trial registered at https://
clinicaltrial.gov, identiﬁer NCT02477319, and we obtained these data
through application to the US CFF at https://www.cff.org/researchers/cffoundation-biorepository.

Study design
The CGMS is a registry-based observational genetics study. The US Part B
Cystic Fibrosis Foundation (CFF) Therapeutics PROSPECT study is an
observational study of modulator treatment. The current study
investigates the relationship between rs7512462 and lung function
pre- and post-CFTR modulators in Canadian and US CF cohorts; in the
general population; and in a case control study of chronic obstructive
pulmonary disease (COPD).
Clinical data collected as part of the CGMS include forced expiratory
volume in 1 s (FEV1), age, sex, and height which are all obtained from the
Canadian CF Patient Data Registry (CCFRD), with occasional augmentation
by chart review at the participating sites. Genetic data is linked to clinical
data through an approved data access agreement with Cystic Fibrosis
Canada. Part B of the CFF Therapeutics PROSPECT observational study34
(https://clinicaltrials.gov/ct2/show/NCT02477319) in the US evaluated the
effectiveness of LUM/IVA and collected buffy coat and clinical data from
individuals with two copies of the Phe508del variant who were prescribed
LUM/IVA. We received the PROSPECT study buffy coat and corresponding
clinical data from the US CFF and extracted DNA for genotyping.
npj Genomic Medicine (2022) 28

Sample genotyping and quality control
DNA from the CGMS participants (n = 2736) were genotyped on four
Illumina genome-wide platforms: the 610Quad, 660 W, Omni5 (see Gong
et al.1 for details), and Omni2.5 BeadChip. The PROSPECT samples (n = 168)
were genotyped on the Illumina Omni2.5 BeadChip at The Centre for
Applied Genomics, The Hospital for Sick Children. Genotype calling was
performed using Genome Studio V2011.1. Quality control (QC) of
genotypes were done separately by genotyping platform as in Gong
et al.1 and imputed to a hybrid reference panel consisting of the 1000
Genomes reference and 101 Canadian CGMS participants sequenced at
30X coverage by Complete Genomics62.

Phenotypes, sampling and inclusion criteria
Lung function severity in the absence of modulator treatment for
participants in CGMS was measured by Saknorm, the survival adjusted
average CF-speciﬁc Kulich FEV1 percentiles that are normalized using 3
years of data in samples 6 years or older5,31,35. For participants whose
recruitment year was after 2008, Saknorm is calculated using Canadian CFspeciﬁc reference equations from 2008 to 201463, rather than US reference
equations64. Saknorm enables comparison of CF lung disease across the
age spectrum where there is differential mortality and is therefore used as
a phenotype in CF genetic association studies. After quality control (QC),
n = 89 participants with at least one gating mutation, n = 1266 with
homozygosity for Phe508del and n = 63 with two MF alleles in trans are
included in the analysis. Of these participants, 54 individuals with at least
one gating mutation and 1013 who are homozygous for Phe508del were
also included in a previous publication31 (Fig. 1).
CGMS participants prescribed IVA or LUM/IVA were also included in the
treatment response study, together with the US PROSPECT participants for
LUM/IVA (Fig. 1, Table 1). Similar to Strug et al.31, all participants included
for modulator lung response analysis had a baseline measurement
between 30 and 96 FEV1pp measured within 3 months prior to, or on,
the treatment initiation date. The CGMS data is obtained from the CCFRD
with variable longitudinal entry depending on the resources of the
individual clinics across the country while PROSPECT collected regular
measurements at 1, 3, 6, and 12 months after treatment initiation.
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To account for this difference, the LUM/IVA treatment response is deﬁned
as the difference in FEV1pp between the ﬁrst visit on treatment within
5–7 months and that measured at baseline following convention in the
literature65. For the IVA study, aligned with reported treatment responses
seen by 15 days10, the difference between mean FEV1pp within 15 to
400 days to FEV1pp baseline31, as well as the difference between the
longitudinal FEV1pp within 15 to 400 days to FEV1pp baseline are used.
We also investigated an IVA analysis with treatment response deﬁned as
the difference from the ﬁrst FEV1pp within 15 to 60 days after the treatment
initiation; the conclusion is comparable but because the sample size is
reduced to 33, we report the mean treatment response and longitudinal
treatment response in 15 to 400 days. After phenotype and genotype QC,
91 participants from PROSPECT and 104 CGMS participants were included
in the genetic analysis for LUM/IVA and 45 for the IVA study (see
Supplementary Table 1 for sample exclusion; Fig. 1).
We also investigated CFTR function in 46 CF Canada SickKids Program in
CF Individualized Therapy39 (CFIT) participants homozygous for Phe508del
whose nasal epithelia were brushed, cultured to passage 2 (P2) and
mounted in a circulating Ussing chamber. Thirty-six individuals who
underwent brushing prior to modulator initiation and for whom we had
rs7512462 genotype are included in the Ussing chamber analysis (Fig. 1).
A subset of the CGMS cohort (n = 82; Fig. 1) and 6 healthy controls had
RNA from their nasal cells sequenced as part of CFIT. In addition, we have
sequenced nasal cells for 9 CFIT samples cultured to passage 3 (P3) at twotime points (14–16 days and 26–30 days). We also sequenced the RNA
from de-identiﬁed CF individuals who underwent lung transplantation,
obtained from paired human bronchial and nasal epithelia; n = 17
independent pairs of uncultured primary HNE and HBE; and n = 16
cultured HNE and HBE pairs. The HBE samples were collected by
bronchoscopy, using a bronchoscopic cytology brush to brush the
bronchial airway lumen proximal to the anastomosis. HNE samples were
collected by nasal brushing from the inferior turbinate using a 3 mm
diameter sterile cytology brush (MP Corporation, Camarillo, CA).
Illumina Smart-Seq2 single-cell RNA data from three individuals were
obtained from the Human Lung Cell Atlas40. The donors consisted of two
males and one female, aged between 46 to 75 years. The samples were
freshly resected lung tissues obtained during surgery with conﬁrmed
normal histology (except for very mild emphysema in some of the samples
from one individual).
Summary association statistics from other GWAS phenotypes were
obtained from the GWAS ATLAS44 (See Methods subsection PheWAS data
extraction and Colocalization with CF GWAS summary statistic). Association
between rs7512462 and lung function in a non-CF population was
assessed using the UK Biobank data under application #40946, or was
investigated using summary statistics from Shrine et al.33 when available.

Association analyses of rs7512462
To assess whether rs7512462 was associated with Saknorm in the different
CFTR genotype groups, we carried out a stratiﬁed analysis, separately for
those with gating variants (or the subset speciﬁcally with G551D), those
homozygous for Phe508del and those with two minimal function (MF)
variants, using both additive and recessive models. In each CFTR genotype
subgroup, the association analysis used the R package ‘rms’66 to obtain a
robust variance estimator and the linear regression included an indicator
for which reference cohort was used to calculate the Saknorm phenotype.
For individuals with at least one G551D variant, the rs7512462 association
in CGMS is meta-combined with that from four previously published
cohorts: a cohort from France32 and 3 from the United States36. For CF
individuals homozygous for Phe508del or for those with at least one gating
mutation, the rs7512462 association results are also meta-combined with
those reported in Corvol et al.32. Meta-analysis is implemented using
inverse variance and sample size weighting with the R functions ‘metagen’
in the package ‘meta’67 and ‘rma’ in the package ‘metafor’68, respectively
and the R package ‘forestplot’ is used to generate forest plots69. To assess
whether lung function is different between the three CFTR genotype
groups, we regressed Saknorm on two indicators for the three CFTR
genotype categories. Additionally, to assess whether the effects of
rs7512462 genotype on Saknorm were different between the three CFTR
genotype groups, we included a SNP-CFTR interaction term in the
regression model and performed an F-test using the aov function. All
analyses adjusted for the reference cohort used to calculate Saknorm and
only two-sided p-values less than 0.05, and with the direction that the C
allele is beneﬁcial, are considered signiﬁcant.
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We also use multivariable regression with robust variance estimation to
assess the association of rs7512462 with the modulator FEV1pp response,
where rs7512462 is coded recessively to align with what is observed in
exploratory data analysis (Fig. 2). For the association with treatment
response to IVA, covariates include age and FEV1pp at baseline. To account
for the variable follow-up days and the variable baseline measurement
time prior to the treatment initiation, we also implement a linear mixedeffect model for participants on IVA and with follow-up measurements
between 15 to 400 days using the R function ‘lmer’ in the package ‘lme4’
with a random intercept70. For treatment response to LUM/IVA, besides
rs7512462, age and FEV1pp at baseline, principal components (PCs) were
also included to adjust for population structure, which were calculated
from the PROSPECT or the combined CGMS and PROSPECT studies by the
R function PC-AiR in the GENESIS package71,72 using the kinship matrix
estimated by KING 2.2.473. The signiﬁcant PCs were selected based on the
Tracy-Widom test using the function twtable in POPGEN of Eigensoft74; 7
PCs were included for the US PROSPECT analysis and 4 PCs for the US
PROSPECT + CGMS combined analysis. Analysis of the Ussing chamber
data to assess association of CFTR functional response to CFTR modulators
with rs7512462 uses multivariable regression with a robust variance
estimator, adjusted for a binary indicator of culture media. The boxplots
are obtained using the functions ggplot and geom_boxplot from the
package ggplot2 in R75 and the function geom_jitter from ggplot2 is used
to overlay the individual measurements in a stripchart.
Genetic association analyses for spirometry measures in the UK Biobank
were conducted using imputed (v3) phenotypic data obtained from the UK
Biobank76,77. In-house scripts, R package rbgen and C++ tool bgenix78,
were used to index, subset and perform association analysis using imputed
dosage76. COPD was deﬁned according to the GOLD (levels 2 to 4) criteria
of moderate to very severe airﬂow limitation48 (FEV1/FVC ratio < 0.7 and
FEV1pp < 80%). Prior to analysis, spirometry and genotyping quality control
(QC) were carried out as suggested in Shrine et al.33, with the exception of
kinship and ethnicity analyses, where we opted to use KING’s (v.2.0)
–unrelated option73 and the UKBB’s UID 22006 for the identiﬁcation of
Europeans. This QC method is more conservative and yielded 263,461
participants compared to 321,047 participants in Shrine et al.33. We
removed individuals with incomplete data for sex (UID = 22001), age (UID
= 21022), height (UID = 50), and smoking status (ever/never, UID = 20160).
FEV1pp was calculated using the Global Lung Initiative (GLI) calculator using
the best FEV1, age (UID = 21022), height (UID = 50), and sex (UID = 22001).
From these, 22,071 participants ﬁt the spirometrically-deﬁned COPD
criteria. Summary statistics for population-level GWAS of spirometry (FEV1/
FVC ratio and PEF) were obtained from a meta-analysis of the UKBB and
SpiroMeta Consortium33. Phenotypic analysis at the SLC26A9 locus
included the best measures for PEF, FEV1pp, and FEV1/FVC ratio. The best
measure for FEV1 (UID = 20150) and FVC (UID = 20151) were deﬁned as
the highest measure from the array of values of up to three blows (UID =
3063 and 3062, respectively) that were deemed acceptable according to
blow quality metrics (UID = 20031): “blank”, “ACCEPT”, “BELOW6SEC
ACCEPT” and “BELOW6SEC”; and a back-extrapolated volume (derived
from the blow curve time series, UID = 3066) greater than 5% or less than
150 mL, as explained in Shrine et al.33. The best FEV1/FVC is calculated from
the selected best FEV1 and FVC after determining blow reproducibility
within 250 mL from any other blow as explained in Shrine et al.33. Principal
components were calculated using ﬂashPCA2 v2.179 which is designed for
Biobank-scale data. All association models included three principal
components, sex, age, age2, sex × age, sex × age2, and smoking (ever/
never). All spirometry measures were inverse rank normal transformed
prior to association analysis using the RNOmni R package’s (v0.7.1)
rankNorm function80. Association summary statistics from each of the lung
function phenotypes were then used for colocalization analysis in
LocusFocus v1.4.946.

Phasing and haplotype analysis of CGMS in CF participants
homozygous for Phe508del
SHAPEIT version 4.2.081 was used to completely phase a multi-sample VCF
from n = 447 CGMS participants sequenced using 10X Genomics linkedread genome sequencing technology (10XG; available at https://www.
cysticﬁbrosis.ca/our-programs/cf-registry/requesting-canadian-cf-registrydata); so that it could be used as a reference panel for imputation in the
region chr1:205903051-205953456 (GRCh38). Then SHAPEIT 4.2.081 was
used again to phase the multi-sample VCF ﬁle from the imputed genotype
data of the CGMS1 using the completely phased VCF from 10XG as the
reference panel. LiftoverVCF from picard tools (v2.18.0; https://gatk.
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broadinstitute.org/hc/en-us/articles/360037060932-LiftoverVcf-Picard-)
was used to lift over the imputed VCF from GRCh38 to GRCh37.
Risk haplotypes that include rs7512462 were reported to associate with
age-of-onset of CF-related diabetes in individuals homozygous for
Phe508del37 and here, we similarly construct these haplotypes and assess
their association with Saknorm. Lam et al.37 constructed the haplotypes
from 41 common SNPs (MAF > 15%) in the same linkage disequilibrium
(LD) block as rs7512462 and found that two common haplotypes are
associated with later CFRD onset (low risk (LR), minor haplotype frequency
[MHF] = 28.4%, p = 1.14 × 10−3) and earlier CFRD onset (high risk (HR),
MHF = 24.1%, p = 4.34 × 10−3) (n = 594) when using PLINK’s haplotype
analysis command (–chap and –each-vs-others).
To mimic this haplotype analysis we used imputed genotype data from
the CGMS1 in individuals homozygous for Phe508del (n = 1266). The
imputed data included 40 of the 41 variants used by Lam et al.37, with
the multi-allelic variant rs144469431 removed. After phasing them with the
n = 447 10XG sequence data, we implemented two analyses. The ﬁrst
analysis used the same PLINK command as in Lam et al.37 in an unrelated
set of CGMS Phe508del/Phe508del participants (n = 1164). The second
analysis was in a larger subset that included related individuals and
conducts haplotype association using linear regression with a robust
variance estimate that accounts for the relatedness (n = 1266), comparing
each of the eight haplotypes studied in Lam et al.37 to a comparison group
that includes all others using an additive model.

Ussing chamber studies with primary human nasal epithelial
cells
Cell monolayers from primary human nasal epithelial (HNE) brushes were
mounted in non-perfused P2300 Ussing chambers containing Krebs
Bicarbonate buffer (126 mM NaCl, 24 mM NaHCO3, 2.13 mM K2HPO4,
0.38 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2 and 10 mM glucose). The
buffer solution was maintained at pH 7.4 and 37 °C and continuously
gassed with a 5% CO2/95% O2 mixture. Transepithelial voltage was
recorded using a VCCMC6 ampliﬁer (Physiologic Instruments, San Diego
CA) in open-circuit mode and the baseline resistance was measured,
following brief 1 µA current pulses every 30 s83 to obtain calculated
equivalent short-circuit currents (Ieq), which was calculated using Ohm’s
law. Passage 2 conﬂuent cultures were treated with either 0.1% DMSO or
CFTR modulators: acute application of Vx770 with 3 µM VX-809 (Selleckchem Cedarlane, Canada) or 3 µM VX809 + 1 µM of an experimental
ampliﬁer (Proteostasis Boston, USA; 42) added to the basolateral ALI media
for 24–48 h83 prior to Ussing experiments. CFTR function was assessed
following inhibition of the epithelial Na+ channel with amiloride (30 µM,
Spectrum Chemical, Gardena, CA) and following cAMP activation with
forskolin (10 µM, Sigma-Aldrich, US) in the above treated monolayers.
Forskolin-stimulated currents mediated by CFTR were measured as change
in current after application of forskolin (ΔIeq-forskolin; µA/cm2). The
genotype data from the CGMS enabled stratiﬁcation of CFTR function by
rs7512462 genotype to determine whether increased function correlated
with genotype upon exposure to the drugs.

Cell culturing
Cell culturing was carried out in the same manner as described
previously82 for HNE samples from 9 CFIT participants used to investigate
expression differences with culturing time (14 versus 28 days); for the 16
paired cultured HNE and HBE samples used to investigate the difference in
SLC26A9 expression across these model systems; and for 46 nasal brushes
from individuals homozygous for Phe508del enrolled in the CGMS that
were studied in Ussing chamber. Brieﬂy, nasal epithelial cells were isolated
and expanded to passage 1 from nasal brushes in the expansion media
PneumaCult™ Ex (STEMCELL Technologies) containing 5 μM Rho Kinase
inhibitor Y27632 (Selleck Chemicals) and an antibiotic cocktail (penicillin
100 units/mL, streptomycin 100 µg/mL, amphotericin 0.25 µg/mL, tobramycin 80 µg/mL, vancomycin 16 µg/mL, metronidazole 32 µg/mL, meropenem 8 µg/mL, septra (trimethoprim/sulfamethoxazole) 16/80 µg/mL,
colistimethate 6 µg/mL). A subset of earlier enrolled samples for Ussing
chamber study were cultured using an alternative media using an
antibiotic cocktail including penicillin 100 units/mL, streptomycin 100 µg/
mL, and amphotericin 0.25 µg/mL. We refer to this alternative media as
non-standard media in the analysis.
These expanded cells from homozygous Phe508del samples were
seeded to collagen-coated Transwell inserts (6.5 mm diameter, 0.4 μm pore
size, Corning) at a seeding density of 1 × 105 cells per well at passage 2
(P2). Upon conﬂuency, the basolateral media was changed to differentiation media PneumaCult™ ALI (STEMCELL Technologies) containing
penicillin 100 units/mL and streptomycin 100 µg/mL. The media was
refreshed daily for 7 days then alternate days and any ﬂuid collecting in
the apical side was carefully aspirated until the cells reached approximately
air-liquid interface (ALI) day 14 for Ussing studies.
Expanded cells for RNA sequencing were further expanded in
PneumaCult™ Ex plus (STEMCELL Technologies) media containing the
antibiotic cocktail (penicillin 100 units/mL, streptomycin 100 µg/mL,
amphotericin 0.25 µg/mL, tobramycin 80 µg/mL, vancomycin 16 µg/mL,
metronidazole 32 µg/mL, meropenem 8 µg/mL, septra (trimethoprim/
sulfamethoxazole) 16/80 µg/mL, colistimethate 6 µg/mL). Passage 3 cells
were seeded in collagen-coated Transwell inserts (6.5 mm diameter,
0.4 μm pore size, Corning) at a seeding density of 1 × 105 cells per well.
The cells were maintained in Pneumacult™ Ex plus media until the
Transwells were fully conﬂuent. Upon conﬂuency, the media was
changed to differentiation media PneumaCult™ ALI (STEMCELL Technologies). These cells were maintained in an air liquid interface by changing
the basolateral media daily for a period of one week, following which the
media was changed on alternate days for a period of 14 to 28 days. The 9
HNE samples to study the expression difference at different culture times
were sequenced at two time points (14–16 days and 26–30 days) and the
paired HNE and HBE samples were well-differentiated by 3 weeks before
undergoing sequencing.
npj Genomic Medicine (2022) 28

RNA sequencing, quality control, and analysis
The CF human nasal epithelia (HNE) cells were sequenced on the Illumina
HiSeq 2500 platform (Illumina Inc. San Diego, California, USA) and aligned
as described in Eckford et al.39. Expression counts were quantiﬁed using
RNA-SeQC (ver. 2.0.0) and normalized to transcripts per million (TPM)84 as
well as trimmed mean of M values (TMM) measures85.
To compare the expression level for SLC26A9 across the different airway
models, we calculated the TPM from naïve HNE for 82 CGMS participants
and 6 healthy controls, 16 pairs of de-identiﬁed cultured HNE and HBE, 17
pairs of de-identiﬁed naïve HNE and HBE and 9 CFIT cultured HNE samples.
eQTLs were calculated from 79 CGMS participants for whom both
genotype and RNA sequence from naïve HNEs were available (Fig. 1).
Quality control required TPM ≥ 0.1 and read counts ≥ 6 in greater than
20% of the sample to be analyzed. FastQTL (ver. 2.0) was used to conduct
differential gene expression analysis of TMM-normalized read counts on
SNP genotypes86. Covariates included the top 3 genotype principal
components, 15 probabilistic estimation of expression residual (PEER)
factors, sample study source, sex, genotyping platform, RNA integrity
number (RIN) and PTPRC/CD45 gene expression which adjusts for
immune cell composition in the samples. The genotype principal
components and PEER factors were generated using R packages
GENESIS71,72 and PEER87, respectively. The average expression level of
SLC26A9 was compared across HBE and HNE in both cultured and naïve
paired tissues. Paired t-tests were conducted using the t.test() function in
R v3.6.188, based on TPM.
For the Human Lung Atlas single-cell data40, cellular expression proﬁles
were clustered by nearest-neighbor for visualization. RNA count data and
cell annotations provided in this dataset were used; counts were
normalized (library-size corrected) to 1,000,000 reads per cell and logscaled. Scanpy v1.8.289 in Python 3.7 was used for the CFTR and SLC26A9
single-cell expression visualization of the Human Lung Cell Atlas data.
A subset of these samples with expression from more than 500 genes
and greater than 50,000 total mapped reads were used for statistical
modeling of CFTR-SLC26A9 co-expression. Library sizes were normalized
using the TMM method. Log-transformed read counts per million (logCPMs) were generated using the normalized library sizes and were used to
calculate the Spearman’s correlation between the CFTR and the SLC26A9
genes. Expression raw read count from CFTR was regressed on that of
SLC26A9 in the zero-inﬂated negative binomial model analysis with a log
link function. Normalized library size was adjusted using an offset term.
Zero-inﬂation was modelled by the detection rate variable which is the
proportion of genes with expression data in a cell. The effect size estimate
indicates log-ratio relations between CFTR and SLC26A9 expression.
The Spearman’s correlation and the zero-inﬂated negative binomial model
analysis were performed by R function cor.test() and the zeroinﬂ() function
in the package pscl90, respectively.
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PheWAS data extraction and colocalization with CF GWAS
summary statistics
We extracted all studies with signiﬁcant p-values at rs7512462 from the
GWAS ATLAS at https://atlas.ctglab.nl/PheWAS. By querying the SNP
rs7512462 in the ‘search SNPs or Gene’ box, all the studies that pass the
Bonferroni correction are plotted and details about the studies are
presented in the lower part of the webpage, which can be downloaded as
a csv ﬁle from the website. We report the 10 studies with smallest
rs7512462 p-value in the paper. The colocalization analysis with the CF
GWAS summary statistics1 was carried out using LocusFocus (v1.4.8)46.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
Data from the CGMS analyzed for the lung function pre- and post-modulator
treatment are available from the Canadian CF registry at https://www.cysticﬁbrosis.
ca/our-programs/cf-registry/requesting-canadian-cf-registry-data; the functional data
and RNA-seq data from the CGMS is available from the CFIT program at https://lab.
research.sickkids.ca/cﬁt/cystic-ﬁbrosis-patients-families-researchers/, and the paired
cultured and fresh naïve HNE and HBE is available at GEO (GSE172232). The US
PROSPECT data are available by application to the US CFF at https://www.cff.org/
researchers/cf-foundation-biorepository and the study is registered on https://
clinicaltrials.gov/ct2/show/NCT02477319. The single-cell RNA-sequencing data are
downloaded from the Human Lung Cell Atlas at http://hlca.ds.czbiohug.org. The
summary statistics for the pheWAS study are available at https://atlas.ctglab.nl/
PheWAS and the meconium ileus association results that have been used for
colocalization analysis can be downloaded from https://lab.research.sickkids.ca/strug/
publications-software/. The data used for the COPD analysis are available through
application to the UK Biobank.

CODE AVAILABILITY
All code and analysis steps implemented to process the UK Biobank data are
available at https://github.com/strug-hub/UKBB_spirometry_on_COPD. The software
used for colocalization plotting and statistical testing is available at https://locusfocus.
research.sickkids.ca/. The other analyses did not require any custom code and are
described in the Methods Section.

Received: 30 December 2021; Accepted: 4 March 2022;

REFERENCES
1. Gong, J. et al. Genetic association and transcriptome integration identify contributing genes and tissues at cystic ﬁbrosis modiﬁer loci. PLoS Genet. 15,
e1008007 (2019).
2. Miller, M. R. et al. Variants in solute carrier SLC26A9 modify prenatal exocrine
pancreatic damage in cystic ﬁbrosis. J. Pediatr. 166, 1152–1157 (2015). e1156.
3. Soave, D. et al. Evidence for a causal relationship between early exocrine pancreatic disease and cystic ﬁbrosis-related diabetes: A Mendelian randomization
study. Diabetes 63, 2114–2119 (2014).
4. Blackman, S. et al. Genetic modiﬁers of cystic ﬁbrosis-related diabetes. Diabetes
62, 3627–3635 (2013).
5. Corvol, H. et al. Genome-wide association meta-analysis identiﬁes ﬁve modiﬁer
loci of lung disease severity in cystic ﬁbrosis. Nat. Commun. 6, 8382 (2015).
6. Cutting, G. R. Cystic ﬁbrosis genetics: From molecular understanding to clinical
application. Nat. Rev. Genet. 16, 45–56 (2015).
7. Sun, L. et al. Multiple apical plasma membrane constituents are associated with
susceptibility to meconium ileus in individuals with cystic ﬁbrosis. Nat. Genet. 44,
562–569 (2012).
8. Sosnay, P. R. et al. Deﬁning the disease liability of variants in the cystic ﬁbrosis
transmembrane conductance regulator gene. Nat. Genet. 45, 1160–1167 (2013).
9. Strug, L. J., Stephenson, A. L., Panjwani, N. & Harris, A. Recent advances in
developing therapeutics for cystic ﬁbrosis. Hum. Mol. Genet. 27, R173–R186
(2018).
10. Ramsey, B. W. et al. A CFTR potentiator in patients with cystic ﬁbrosis and the
G551D mutation. N. Engl. J. Med. 365, 1663–1672 (2011).

Published in partnership with CEGMR, King Abdulaziz University

11. Howard, M., Frizzell, R. A. & Bedwell, D. M. Aminoglycoside antibiotics restore
CFTR function by overcoming premature stop mutations. Nat. Med. 2, 467–469
(1996).
12. Heijerman, H. G. M. et al. Efﬁcacy and safety of the elexacaftor plus tezacaftor plus
ivacaftor combination regimen in people with cystic ﬁbrosis homozygous for the
F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 394,
1940–1948 (2019).
13. Middleton, P. G. et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic ﬁbrosis with a
single Phe508del allele. N. Engl. J. Med. 381, 1809–1819 (2019).
14. Wainwright, C. E. et al. Lumacaftor-Ivacaftor in patients with cystic ﬁbrosis
homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 220–231 (2015).
15. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11, 237–245 (2012).
16. Haq, I. J., Gray, M. A., Garnett, J. P., Ward, C. & Brodlie, M. Airway surface liquid
homeostasis in cystic ﬁbrosis: pathophysiology and therapeutic targets. Thorax
71, 284–287 (2016).
17. Martin, S. L., Saint-Criq, V., Hwang, T. C. & Csanady, L. Ion channels as targets to
treat cystic ﬁbrosis lung disease. J. Cyst. Fibros. 17, S22–S27 (2018).
18. Balazs, A. & Mall, M. A. Role of the SLC26A9 chloride channel as disease modiﬁer
and potential therapeutic target in cystic ﬁbrosis. Front. Pharm. 9, 1112 (2018).
19. Enterprise Therapeutics. in The 13th European Cystic Fibrosis Basic Science
Conference.
20. Mall, M. A. & Galietta, L. J. Targeting ion channels in cystic ﬁbrosis. J. Cyst. Fibros.
14, 561–570 (2015).
21. Nelson, M. R. et al. The support of human genetic evidence for approved drug
indications. Nat. Genet. 47, 856–860 (2015).
22. Aksit, M. A. et al. Genetic modiﬁers of cystic ﬁbrosis-related diabetes have
extensive overlap with type 2 diabetes and related traits. J. Clin. Endocrinol.
Metab. 105, https://doi.org/10.1210/clinem/dgz102 (2020).
23. Lin, Y. C. et al. Cystic ﬁbrosis-related diabetes onset can be predicted using
biomarkers measured at birth. Genet. Med. 23, 927–933 (2021).
24. Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. Science 369, 1318–1330 (2020).
25. Bertrand, C. A. et al. The CFTR trafﬁcking mutation F508del inhibits the constitutive activity of SLC26A9. Am. J. Physiol. Lung Cell Mol. Physiol. 312, L912–L925
(2017).
26. Bertrand, C. A., Zhang, R., Pilewski, J. M. & Frizzell, R. A. SLC26A9 is a constitutively
active, CFTR-regulated anion conductance in human bronchial epithelia. J. Gen.
Physiol. 133, 421–438 (2009).
27. Salomon, J. J. et al. Generation and functional characterization of epithelial cells
with stable expression of SLC26A9 Cl- channels. Am. J. Physiol. Lung Cell Mol.
Physiol. ajplung 00321 02015, https://doi.org/10.1152/ajplung.00321.2015 (2016).
28. Larsen, M. B. et al. Separating the contributions of SLC26A9 and CFTR to anion
secretion in primary human bronchial epithelia. Am. J. Physiol. Lung Cell Mol.
Physiol. 321, L1147–L1160 (2021).
29. Liu, X. et al. Loss of Slc26a9 anion transporter alters intestinal electrolyte and
HCO3(-) transport and reduces survival in CFTR-deﬁcient mice. Pﬂug. Arch. 467,
1261–1275 (2015).
30. Kmit, A. et al. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in
human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in
F508del/F508del cystic ﬁbrosis patients. Biochim. Biophys. Acta. Mol. Basis Dis.
1865, 1323–1331 (2019).
31. Strug, L. J. et al. Cystic ﬁbrosis gene modiﬁer SLC26A9 modulates airway response
to CFTR-directed therapeutics. Hum. Mol. Genet. 25, 4590–4600 (2016).
32. Corvol, H. et al. SLC26A9 gene is associated with lung function response to
ivacaftor in patients with cystic ﬁbrosis. Front Pharm. 9, 828 (2018).
33. Shrine, N. et al. New genetic signals for lung function highlight pathways and
chronic obstructive pulmonary disease associations across multiple ancestries.
Nat. Genet. 51, 481–493 (2019).
34. Sagel, S. D. et al. Clinical effectiveness of Lumacaftor/Ivacaftor in patients with
cystic ﬁbrosis homozygous for F508del-CFTR. A Clinical Trial. A Clin Trial. Ann. Am.
Thorac. Soc. 18, 75–83 (2021).
35. Taylor, C. et al. A novel lung disease phenotype adjusted for mortality attrition
for cystic ﬁbrosis Genetic modiﬁer studies. Pediatr. Pulmonol. 46, 857–869
(2011).
36. Eastman, A. C. et al. SLC26A9 SNP rs7512462 is not associated with lung disease
severity or lung function response to ivacaftor in cystic ﬁbrosis patients with
G551D-CFTR. J. Cyst. Fibros. https://doi.org/10.1016/j.jcf.2021.02.007 (2021).
37. Lam, A. N. et al. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic ﬁbrosis. J. Clin. Invest. 130, 272–286 (2020).
38. Giuliano, K. A. et al. Use of a high-throughput phenotypic screening strategy to
identify ampliﬁers, a novel pharmacological class of small molecules that exhibit
functional synergy with potentiators and correctors. SLAS Disco. 23, 111–121
(2018).

npj Genomic Medicine (2022) 28

J. Gong et al.

14
39. Eckford, P. D. W. et al. The CF Canada-sick kids program in individual CF therapy:
A resource for the advancement of personalized medicine in CF. J. Cyst. Fibros.
18, 35–43 (2019).
40. Travaglini, K. J. et al. A molecular cell atlas of the human lung from single-cell RNA
sequencing. Nature 587, 619–625 (2020).
41. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science
347, 1260419 (2015).
42. Eraslan, G. et al. Single-nucleus cross-tissue molecular reference maps to decipher
disease gene function. Preprint at https://www.biorxiv.org/content/10.1101/
2021.07.19.452954v1 (2021).
43. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. Science 369, 1318–1330 (2020).
44. Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in
complex traits. Nat. Genet. 51, 1339–1348 (2019).
45. Wang, F., Panjwani, N., Wang, C., Sun, L. & Strug, L. J. A ﬂexible summary statisticsbased colocalization method with application to the mucin cystic ﬁbrosis lung
disease modiﬁer locus. Am. J. Hum. Genet. 109, 253–269 (2022).
46. Panjwani, N. et al. LocusFocus: Web-based colocalization for the annotation and
functional follow-up of GWAS. PLoS Comput. Biol. 16, e1008336 (2020).
47. Stephens, M. B. & Yew, K. S. Diagnosis of chronic obstructive pulmonary disease.
Am. Fam. Physician 78, 87–92 (2008).
48. Mannino, D. M. & Buist, A. S. Global burden of COPD: Risk factors, prevalence, and
future trends. Lancet 370, 765–773 (2007).
49. Pinto, M. C. et al. Synergy in cystic ﬁbrosis therapies: Targeting SLC26A9. Int. J.
Mol. Sci. 22, https://doi.org/10.3390/ijms222313064 (2021).
50. Sato, Y., Thomas, D. Y. & Hanrahan, J. W. The anion transporter SLC26A9 localizes
to tight junctions and is degraded by the proteasome when co-expressed with
F508del-CFTR. J. Biol. Chem. 294, 18269–18284 (2019).
51. Fischer, H. The G551D CFTR chloride channel spurs the development of personalized medicine. J. Physiol. 592, 1907–1908 (2014).
52. Ratjen, F. et al. Cystic ﬁbrosis. Nat. Rev. Dis. Prim. 1, 1–19 (2015).
53. Walter, J. D., Sawicka, M. & Dutzler, R. Cryo-EM structures and functional characterization of murine Slc26a9 reveal mechanism of uncoupled chloride transport. Elife 8, https://doi.org/10.7554/eLife.46986 (2019).
54. Baskurt, Z. et al. VikNGS: A C++ variant integration kit for next generation
sequencing association analysis. Bioinformatics 36, 1283–1285 (2020).
55. Johns, D. P., Walters, J. A. & Walters, E. H. Diagnosis and early detection of COPD
using spirometry. J. Thorac. Dis. 6, 1557–1569 (2014).
56. Cantin, A. M. et al. Cystic ﬁbrosis transmembrane conductance regulator function
is suppressed in cigarette smokers. Am. J. Respir. Crit. Care Med. 173, 1139–1144
(2006).
57. Clunes, L. A. et al. Cigarette smoke exposure induces CFTR internalization and
insolubility, leading to airway surface liquid dehydration. FASEB J. 26, 533–545
(2012).
58. Raju, S. V. et al. Cigarette smoke induces systemic defects in cystic ﬁbrosis
transmembrane conductance regulator function. Am. J. Respir. Crit. Care Med.
188, 1321–1330 (2013).
59. Dransﬁeld, M. T. et al. Acquired cystic ﬁbrosis transmembrane conductance
regulator dysfunction in the lower airways in COPD. Chest 144, 498–506
(2013).
60. Sloane, P. A. et al. A pharmacologic approach to acquired cystic ﬁbrosis transmembrane conductance regulator dysfunction in smoking related lung disease.
PLoS One. 7, e39809 (2012).
61. Mall, M. A. Unplugging mucus in cystic ﬁbrosis and chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 13, S177–S185 (2016).
62. Panjwani, N. et al. Improving imputation in disease-relevant regions: Lessons
from cystic ﬁbrosis. NPJ Genom. Med. 3, 8 (2018).
63. Kim, S. O., Corey, M., Stephenson, A. L. & Strug, L. J. Reference percentiles of FEV1
for the Canadian cystic ﬁbrosis population: Comparisons across time and countries. Thorax 73, 446–450 (2018).
64. Kulich, M. et al. Disease-speciﬁc reference equations for lung function in patients
with cystic ﬁbrosis. Am. J. Respir. Crit. Care Med. 172, 885–891 (2005).
65. Bardin, E. et al. Modulators of CFTR. Updates on clinical development and future
directions. Eur. J. Med. Chem. 213, 113195 (2021).
66. Harrell, F. E. J. Regression Modeling Strategies With Applications to Linear Models,
Logistic and Ordinal Regression, and Survival Analysis. (Springer, 2015).
67. Schwarzer, G. metagen: Generic inverse variance meta-analysis. Preprint at https://
cran.r-project.org/web/packages/meta/meta.pdf (2021).
68. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J. Stat.
Softw. 36, 1–48 (2010).
69. Gordon, M. & Lumley, T. forestplot: Advanced Forest Plot Using ‘grid’ Graphics.
Preprint at https://cran.r-project.org/web/packages/forestplot/forestplot.pdf
(2021).
70. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models
using lme4. J. Stat. Softw. 67, 1–48 (2015).

npj Genomic Medicine (2022) 28

71. Conomos, M. P. Population Structure and Relatedness Inference using the GENESIS
Package, (2021).
72. Conomos, M. P., Miller, M. B. & Thornton, T. A. Robust inference of population
structure for ancestry prediction and correction of stratiﬁcation in the presence of
relatedness. Genet. Epidemiol. 39, 276–293 (2015).
73. Manichaikul, A. et al. Robust relationship inference in genome-wide association
studies. Bioinformatics 26, 2867–2873 (2010).
74. Patterson, N., Price, A. L. & Reich, D. Population structure and eigenanalysis. PLoS
Genet. 2, e190 (2006).
75. Wickham, H. ggplot2: Elegant Graphics for Data Analysis., (Springer-Verlag, 2016).
76. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic
data. Nature 562, 203–209 (2018).
77. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes
of a wide range of complex diseases of middle and old age. PLoS Med 12,
e1001779 (2015).
78. Band, G. & Marchini, J. BGEN: A binary ﬁle format for imputed genotype and
haplotype data. Preprint at https://www.biorxiv.org/content/10.1101/308296v2.
(bioRxiv, 2018).
79. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: Principal component analysis of
Biobank-scale genotype datasets. Bioinformatics 33, 2776–2778 (2017).
80. McCaw, Z. R., Lane, J. M., Saxena, R., Redline, S. & Lin, X. Operating characteristics of the rank-based inverse normal transformation for quantitative
trait analysis in genome-wide association studies. Biometrics 76, 1262–1272
(2020).
81. Delaneau, O., Zagury, J. F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T.
Accurate, scalable and integrative haplotype estimation. Nat. Commun. 10, 5436
(2019).
82. Cao, H. et al. A helper-dependent adenoviral vector rescues CFTR to wild-type
functional levels in cystic ﬁbrosis epithelial cells harbouring class I mutations. Eur.
Respir. J. 56, https://doi.org/10.1183/13993003.00205-2020 (2020).
83. Cao, H. et al. Testing gene therapy vectors in human primary nasal epithelial
cultures. Mol. Ther. Methods Clin. Dev. 2, 1–6 (2015).
84. DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process
optimization. Bioinformatics 28, 1530–1532 (2012).
85. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential
expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
86. Ongen, H., Buil, A., Brown, A. A., Dermitzakis, E. T. & Delaneau, O. Fast and efﬁcient
QTL mapper for thousands of molecular phenotypes. Bioinformatics 32,
1479–1485 (2016).
87. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation
of expression residuals (PEER) to obtain increased power and interpretability of
gene expression analyses. Nat. Protoc. 7, 500–507 (2012).
88. R Core Team. R: A language and environment for statistical computing. Available
online at https://www.R-project.org/. (Vienna, Austria, 2021).
89. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: Large-scale single-cell gene
expression data analysis. Genome Biol. 19, 15 (2018).
90. Zeileis, A., Kleiber, C. & Jackman, S. Regression Models for Count Data in R. Journal
of Statistical Software 27, 1–25 (2018).

ACKNOWLEDGEMENTS
We thank the US CF Foundation for the use of Part B of the PROSPECT observational
study. We thank the Cystic Fibrosis Canada–SickKids Program for Individualized
Therapy for access to the RNA-sequencing of the nasal epithelia. We thank the
patients, care providers and clinic research assistants, collaborators, and principal
investigators involved in CF Centers throughout Canada for their contributions to
the CF Canada Patient Registry and the Canadian CF Gene Modiﬁer Study. Some of
the research was conducted using the UK Biobank Resource under application
Number 40946. We thank Shaf Keshavjee for providing the bronchial cells for
paired analysis of gene expression and Hong Ouyang for culturing the epithelial
cells. We thank Dr. John Miller for providing the ampliﬁer for the study. The authors
wish to acknowledge the staff supporting the High Performance Computing cluster
and research helpdesk department and The Centre for Applied Genomics at the
Hospital for Sick Children, Toronto. Funding was provided by Cystic Fibrosis
Foundation STRUG17PO, MORAES1610; Canadian Institutes of Health Research (FRN
167282); Cystic Fibrosis Canada (2626) and the CFIT Program funded by the
SickKids Foundation and CF Canada; and the Natural Sciences and Engineering
Research Council of Canada (RGPIN-2015- 03742, 250053-2013). This work was also
funded by the Government of Canada through Genome Canada (OGI-148) and
supported by a grant from the Government of Ontario. The funders of the study
play no role in study design, data collection, and analysis, decision to publish, or
preparation of the manuscript.

Published in partnership with CEGMR, King Abdulaziz University

J. Gong et al.

15
AUTHOR CONTRIBUTIONS

ADDITIONAL INFORMATION

L.J.S. conceptualized the study and the design. C. Bartlett, F.L., K.K., J.A., A.H., M. Shaw,
M.E., G.C-M., D.A., S.B., C. Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., L.B., D.M-C., D.H.,
M.J.S., N.M., J.B., E.T., A.L.S., B.S.Q., P.W., W.M.L., M. Solomon, E.B., T.J.M., T.G., F.R.
enrolled the participants and collected the biospecimens. J.G., G.H., C.W., N.P., S.M.,
L.J.S. carried out the statistical and bioinformatic analyses, created the visualizations,
and constructed the tables and Figures. L.S., T.G, J.M.R and L.J.S. provided important
insights to interpret the results and clarify the technical details for the methods,
J.G., G.H., C.W., N.P., J.M.R., L.J.S. wrote the paper and all authors edited the paper.
All authors have read and approved the ﬁnal manuscript.

Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41525-022-00299-9.

COMPETING INTERESTS
L.B. participated in a Vertex Virtual Advisory Board and she is a member of the CF
Annual Faculty, sponsored by Vertex Pharmaceuticals. D.M-C. received an honorarium
for teaching module development for Vertex Pharmaceuticals. N. M. is doing contract
research trials for Vertex Pharmaceuticals and Abbvie. A.L.S. has received speaking
fees for educational programs sponsored by Vertex Pharmaceuticals. B.S.Q. has
received speaker fees from Vertex Pharmaceuticals and has served as site PI for
several Vertex-sponsored clinical trials. W.M.L. is a study investigator for Vertex
Pharmaceuticals. E.T., T.G., and F.R. act as a consultant for Vertex Pharmaceuticals.
M.S. participated in Vertex clinical trials and received payment for education
modules. J.G., G.H., C.W., C. Bartlett, N.P., S.M., F.L., K.K., J.A., A.H., M.S., M.E., G.C-M.,
D.A., S.B., C.Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., D.H., M.J.S., J.B., P.W., L.S., E.B.,
T.M., J.M.R, and L.J.S. have no conﬂicts of interest.

Published in partnership with CEGMR, King Abdulaziz University

Correspondence and requests for materials should be addressed to Lisa J. Strug.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2022

npj Genomic Medicine (2022) 28

